滚动资讯
AgilentBoston Trust Walden Corp Sells 21,880 Shares of Agilent Technologies, Inc. $A - MarketBeatThermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Borrow Rate - Xã Thanh HàAgilentIs Agilent Technologies a Better Buy Than Danaher? - TrefisLonza NewsLonza集团(SWX:LONN)股价近期波动后是否定价过高?-雅虎财经Thermo Fisher赛默飞世尔科技公司第四季度财报后股价下跌2.95%,尽管每股收益微超预期且营收同比增长3.9%。FierceBiotech礼来公司放弃与瑞格生物剩余协议,RIPK1抑制剂再遭打击。Thermo FisherThermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.comWatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn LaFierceBiotech麦克森以12.5亿美元将外科部门少数股权置换给阿波罗基金。FierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1B
BioWorld 2026年2月4日

首创融合蛋白在多模型中逆转T细胞耗竭

首创融合蛋白在多模型中逆转T细胞耗竭

暂时没有全文,请查看原始来源。